GLUE · Monte Rosa Therapeutics, Inc.
$14.78
-0.99 (-6.28%)
At close · Aug 20
Market Cap
$1.35B
Shares
85.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.78
Open$15.62
Day$14.72–15.90
52W close$4.43–25.31
Avg vol 30d1.4M
Short int16.5M · 19.3% float · 10.6d
Short vol56%
Last earningsMar 17, 2026
DataJun 2021–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−26%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−36%
trailing
6-month return
−17%
trailing
YTD return
−6%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +28 funds added
Insider flow
Distributing
Net -$451.3K over 90 days · 100% sells
Short interest
Falling
19.29% of float · ▼ -4.3% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
193 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+64%
Y/Y
Free cash flow
$-27.5M
Balance sheet
$129.9M
net cash
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $20 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +28 funds added
Insider flow
Distributing
Net -$451.3K over 90 days · 100% sells
Short interest
Falling
19.29% of float · ▼ -4.3% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
193 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $15 · 50%
Range high $25
vs 200-day avg -20%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GLUE
this stock
Monte Rosa Therapeutics, Inc.
|
$1.35B | -5.7% | +63.5% | — | 19.3% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GLUE | -6.7% | -35.8% | -16.7% | -10.5% | -5.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -4.7% | -39.1% | -27.9% | -12.6% | -17.6% |
Key facts
CIK
1826457
CUSIP
61225M102
13F (30d)
186 filings
183 filers
Visit website
Investor relations